Spots Global Cancer Trial Database for adenocarcinoma of the prostate
Every month we try and update this database with for adenocarcinoma of the prostate cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Defined Green Tea Catechins in Treating Patients With Prostate Cancer Undergoing Surgery to Remove the Prostate | NCT00459407 | Adenocarcinoma ... Stage I Prostat... Stage II Prosta... | defined green t... placebo immunohistochem... immunoenzyme te... laboratory biom... biopsy mass spectromet... high performanc... | 18 Years - | National Cancer Institute (NCI) | |
| Neoadjuvant Bevacizumab Plus Docetaxel in High Risk Patients With Prostate Cancer Undergoing Radical Prostatectomy | NCT00321646 | Prostate Cancer Adenocarcinoma ... | Bevacizumab Docetaxel | 18 Years - | Dana-Farber Cancer Institute | |
| Calcitriol and Dexamethasone Before Radical Prostatectomy in Treating Patients With Localized Adenocarcinoma (Cancer) of the Prostate | NCT00084864 | Prostate Cancer | calcitriol dexamethasone clinical observ... | 18 Years - 120 Years | Roswell Park Cancer Institute | |
| Hormone Therapy Followed By Internal Radiation Therapy in Treating Patients With Locally Recurrent Prostate Cancer | NCT00032006 | Prostate Cancer | brachytherapy radiation thera... | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Pilot Study of 18F-DCFPyL PET/CT in the Evaluation of Men With an Elevated PSA Following Radical Prostatectomy | NCT02523924 | Adenocarcinoma ... | 18F-DCFPyL | 18 Years - 100 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Stereotactic Radiation Therapy in Treating Patients With Prostate Cancer | NCT00619515 | Prostate Cancer | questionnaire a... implanted fiduc... stereotactic ra... | - 120 Years | Case Comprehensive Cancer Center | |
| Zoledronate in Preventing Skeletal (Bone)-Related Events in Men Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metastases | NCT00079001 | Metastatic Canc... Prostate Cancer | zoledronic acid placebo androgen depriv... GnRH agonist Calcium supplem... Vitamin D | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Docetaxel Plus Lycopene in Castration Resistant, Chemotherapy-Naïve Prostate Cancer Patients | NCT01882985 | Adenocarcinoma ... Recurrent Prost... Stage I Prostat... Stage IIA Prost... Stage IIB Prost... Stage III Prost... | Docetaxel Lycopene | 21 Years - | University of California, Irvine | |
| A Registry to Observe the Treatment of Prostate Cancer Under Routine Medical Care | NCT02236637 | Prostate Cancer | 18 Years - | Janssen Pharmaceutica N.V., Belgium | ||
| Radiation Therapy With or Without Goserelin in Treating Patients Who Have Undergone Surgery for Recurrent or Refractory Prostate Cancer | NCT00423475 | Prostate Cancer | goserelin aceta... adjuvant therap... radiation thera... | 18 Years - 120 Years | UNICANCER | |
| Orteronel Maintenance Therapy in Patients With mCRPC Previously Treated With Novel Hormonal Agents | NCT02053311 | Prostate Cancer | Orteronel Placebo | 18 Years - | Swiss Group for Clinical Cancer Research | |
| Vaccine Therapy in Treating Patients With Advanced Adenocarcinoma of the Prostate (Prostate Cancer) | NCT00005039 | Adenocarcinoma ... Recurrent Prost... Stage IV Prosta... | recombinant fow... recombinant vac... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Paclitaxel and Bryostatin 1 in Treating Patients With Metastatic Prostate Cancer | NCT00005028 | Prostate Cancer | bryostatin 1 paclitaxel | 18 Years - | University of Maryland, Baltimore | |
| Sodium Selenite and Radiation Therapy in Treating Patients With Metastatic Cancer | NCT02184533 | Adenocarcinoma ... Hormone-resista... Recurrent Prost... Stage IV Prosta... Multiple Myelom... Plasmacytoma | sodium selenite radiation thera... laboratory biom... pharmacological... questionnaire a... | 18 Years - | Stanford University | |
| Triptorelin and Radiation Therapy in Treating Patients Who Have Undergone Surgery for Intermediate-Risk Stage III or Stage IV Prostate Cancer | NCT00667069 | Prostate Cancer | triptorelin adjuvant therap... 3-dimensional c... | 18 Years - | UNICANCER | |
| Provenge Followed by Docetaxel in Castration-Resistant Prostate Cancer | NCT02793219 | Prostate Cancer | Sipuleucel-T Docetaxel | 18 Years - | The University of Texas Health Science Center, Houston | |
| Radical Prostatectomy in Treating Patients With Locally Advanced Prostate Cancer | NCT00027794 | Prostate Cancer | conventional su... | - 70 Years | European Organisation for Research and Treatment of Cancer - EORTC | |
| Docetaxel Plus Estramustine in Treating Patients With Metastatic Prostate Cancer | NCT00002775 | Prostate Cancer | docetaxel estramustine ph... | 18 Years - | National Cancer Institute (NCI) | |
| Zoledronate and BMS-275291 in Treating Patients With Prostate Cancer | NCT00039104 | Adenocarcinoma ... Recurrent Prost... Stage IV Prosta... | rebimastat zoledronic acid laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Docetaxel and Prednisone With or Without Bevacizumab in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy | NCT00110214 | Adenocarcinoma ... Hormone-resista... Recurrent Prost... Stage IV Prosta... | docetaxel placebo prednisone bevacizumab laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Mitoxantrone Following Surgery in Treating Patients With Prostate Cancer at High Risk for Recurrence | NCT00003858 | Prostate Cancer | mitoxantrone hy... | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Calcitriol and Carboplatin in Treating Patients With Stage IV Prostate Cancer That Has Not Responded to Hormone Therapy | NCT00017576 | Prostate Cancer | calcitriol carboplatin | 18 Years - 120 Years | OHSU Knight Cancer Institute | |
| Low-Fat, High-Fiber Diet Compared to a Standard Diet in Treating Patients With Prostate Cancer | NCT00020995 | Prostate Cancer | therapeutic die... | 40 Years - 80 Years | National Cancer Institute (NCI) | |
| Triptorelin and Radiation Therapy in Treating Patients Who Have Undergone Surgery for Intermediate-Risk Stage III or Stage IV Prostate Cancer | NCT00667069 | Prostate Cancer | triptorelin adjuvant therap... 3-dimensional c... | 18 Years - | UNICANCER | |
| Gene Mutations in Patients With Advanced Prostate Cancer That Is Not Responsive to Hormone Therapy | NCT00002924 | Prostate Cancer | mutation analys... | - | Alliance for Clinical Trials in Oncology | |
| Gefitinib and Etoposide in Treating Patients With Advanced Prostate Cancer That Did Not Respond to Hormone Therapy | NCT00483561 | Prostate Cancer | Gefitinib plus ... | 19 Years - 120 Years | University of Nebraska | |
| BrUOG 337: Olaparib Prior to Radical Prostatectomy For Advanced Prostate Cancer Defects in DNA Repair Genes | NCT03432897 | Prostate Cancer Adenocarcinoma ... | Olaparib Pill Prostatectomy | 18 Years - | Brown University | |
| Bicalutamide and Raloxifene in Treating Patients With Metastatic or Hormone-Refractory Prostate Cancer | NCT01050842 | Prostate Cancer Adenocarcinoma ... Hormone-resista... Stage IV Prosta... | bicalutamide raloxifene quality-of-life... | 18 Years - | Mayo Clinic | |
| A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer | NCT06067841 | Metastatic Cast... | BMS-986460 | 18 Years - | Bristol-Myers Squibb | |
| Nivolumab and BMS-986253 for Hormone-Sensitive Prostate Cancer (MAGIC-8) | NCT03689699 | Prostate Cancer Adenocarcinoma ... | Nivolumab Degarelix BMS-986253 | 18 Years - 99 Years | Columbia University | |
| Radiation Therapy and Docetaxel in Treating Patients Who Are Undergoing Surgery for Localized Prostate Cancer | NCT00321698 | Prostate Cancer | Intensity-Modul... Docetaxel+IMRT | 18 Years - 100 Years | OHSU Knight Cancer Institute | |
| Ketoconazole, Hydrocortisone, and GM-CSF in Treating Patients With Progressive Prostate Cancer After Hormone Therapy | NCT00309894 | Prostate Cancer | sargramostim ketoconazole therapeutic hyd... | - 120 Years | University of California, San Francisco | |
| Effect of Quercetin on Green Tea Polyphenol Uptake in Prostate Tissue From Patients With Prostate Cancer Undergoing Surgery | NCT01912820 | Adenocarcinoma ... Recurrent Prost... Stage I Prostat... Stage IIA Prost... Stage IIB Prost... Stage III Prost... Stage IV Prosta... | green tea extra... quercetin placebo therapeutic con... laboratory biom... | 40 Years - 75 Years | Jonsson Comprehensive Cancer Center | |
| Atrasentan and Zometa for Men With Prostate Cancer Metastatic to Bone | NCT00181558 | Prostate Cancer Adenocarcinoma ... | Atrasentan Zoledronic Acid... | 18 Years - | Massachusetts General Hospital | |
| Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer | NCT01546987 | Prostate Cancer | GnRH agonist Anti-androgen TAK-700 Radiation thera... | 18 Years - | Radiation Therapy Oncology Group | |
| Combination Chemotherapy Plus Filgrastim in Treating Patients With Stage IV Prostate Cancer That Has Not Responded to Hormone Therapy | NCT00005810 | Prostate Cancer | filgrastim carboplatin docetaxel estramustine ph... | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Toremifene Followed by Radical Prostatectomy in Treating Patients With Stage I or Stage II Prostate Cancer | NCT00020735 | Prostate Cancer | toremifene conventional su... neoadjuvant the... | 18 Years - 120 Years | University of Pittsburgh | |
| Radiation Therapy in Treating Patients With Prostate Cancer | NCT01434290 | Prostate Cancer Psychosocial Ef... Radiation Toxic... Sexual Dysfunct... | 36.25 Gy IMRT 51.6 Gy IMRT | 18 Years - | Radiation Therapy Oncology Group | |
| Docetaxel Plus Estramustine in Treating Patients With Metastatic Prostate Cancer | NCT00002775 | Prostate Cancer | docetaxel estramustine ph... | 18 Years - | National Cancer Institute (NCI) | |
| Docetaxel, Prednisone, and Vatalanib in Treating Patients With Advanced Prostate Cancer | NCT00293371 | Prostate Cancer | docetaxel prednisone vatalanib | 18 Years - | University of California, San Francisco | |
| Changes in DNA After Radiation Therapy in Patients With Prostate Cancer | NCT00899912 | Prostate Cancer | microarray anal... diagnostic labo... | 18 Years - | Radiation Therapy Oncology Group | |
| Sorafenib in Treating Patients With Metastatic or Recurrent Prostate Cancer | NCT00093457 | Prostate Cancer | sorafenib tosyl... | 18 Years - 120 Years | Canadian Cancer Trials Group | |
| Computer Planned Radiation Therapy in Treating Patients With Prostate Cancer | NCT00003104 | Prostate Cancer | radiation thera... | - | Memorial Sloan Kettering Cancer Center | |
| Biological Therapy in Treating Patients With Prostate Cancer | NCT00039299 | Prostate Cancer | therapeutic aut... | - | National Cancer Institute (NCI) | |
| Magnetic Resonance Imaging and Magnetic Resonance Spectroscopic Imaging in Diagnosing the Extent of Disease in Patients With Prostate Cancer | NCT00032058 | Prostate Cancer | magnetic resona... magnetic resona... | 18 Years - | National Cancer Institute (NCI) | |
| Lycopene or Omega-3 Fatty Acid Nutritional Supplements in Treating Patients With Stage I or Stage II Prostate Cancer | NCT00402285 | Prostate Cancer | lycopene supple... fish oil supple... Placebo | - | University of California, San Francisco | |
| S0354, Anti-IL-6 Chimeric Monoclonal Antibody in Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy | NCT00433446 | Prostate Cancer | CNTO 328 | 18 Years - | SWOG Cancer Research Network | |
| Plasma and Urine Samples From Patients With Hormone-Refractory Prostate Cancer Enrolled on Clinical Trials CALGB-9480 or CALGB-9583 | NCT00898833 | Prostate Cancer | laboratory biom... | 18 Years - | Alliance for Clinical Trials in Oncology | |
| S0032, Combination Chemotherapy Plus Hormone Therapy in Treating Patients With Metastatic Prostate Cancer | NCT00028769 | Prostate Cancer | bicalutamide estramustine etoposide flutamide goserelin leuprolide nilutamide paclitaxel | 18 Years - | SWOG Cancer Research Network | |
| Celecoxib in Treating Patients With Relapsed Prostate Cancer Following Radiation Therapy or Radical Prostatectomy | NCT00073970 | Prostate Cancer | celecoxib | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Stereotactic Body Radiation Therapy in Treating Patients With Prostate Cancer | NCT00547339 | Prostate Cancer | stereotactic bo... stereotactic bo... stereotactic bo... stereotactic bo... | 18 Years - 120 Years | University of Texas Southwestern Medical Center | |
| Radiation Therapy in Treating Patients With Prostate Cancer | NCT00002480 | Prostate Cancer | radiation thera... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Hormone Therapy With or Without Squalamine Lactate in Treating Patients Who Are Undergoing a Radical Prostatectomy for Locally Advanced Prostate Cancer | NCT00244920 | Prostate Cancer | bicalutamide leuprolide acet... squalamine lact... adjuvant therap... antiandrogen th... antiangiogenesi... conventional su... neoadjuvant the... releasing hormo... | 18 Years - | OHSU Knight Cancer Institute | |
| Observation or Radical Treatment in Patients With Prostate Cancer | NCT00499174 | Prostate Cancer | conventional su... brachytherapy external beam r... Biopsies | 18 Years - | Canadian Cancer Trials Group | |
| Androgen Ablation With or Without Docetaxel in Treating Patients With Advanced Prostate Cancer | NCT00796458 | Pain Prostate Cancer | docetaxel releasing hormo... | 18 Years - | National Cancer Institute (NCI) | |
| Abiraterone Prednisone and Hormonal Therapy Before and During Radiation Therapy in Localized Prostate Cancer | NCT01023061 | Adenocarcinoma ... Stage II Prosta... Stage III Prost... Stage IV Prosta... | abiraterone ace... prednisone leuprolide acet... laboratory biom... external beam r... goserelin aceta... | 18 Years - | University of Washington | |
| Zoledronate in Preventing Skeletal (Bone)-Related Events in Men Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metastases | NCT00079001 | Metastatic Canc... Prostate Cancer | zoledronic acid placebo androgen depriv... GnRH agonist Calcium supplem... Vitamin D | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Hormone Therapy in Treating Patients With Advanced Prostate Cancer | NCT00003026 | Prostate Cancer | bicalutamide flutamide triptorelin radiation thera... | - | European Organisation for Research and Treatment of Cancer - EORTC | |
| Trial of Dasatinib (Sprycel®) in Subjects With Hormone-refractory Prostate Cancer | NCT00570700 | Hormone-refract... Adenocarcinoma ... Hormone-resista... Prostate Cancer Recurrent Prost... | Dasatinib | 18 Years - | University of California, Irvine | |
| Sodium Selenite and Radiation Therapy in Treating Patients With Metastatic Cancer | NCT02184533 | Adenocarcinoma ... Hormone-resista... Recurrent Prost... Stage IV Prosta... Multiple Myelom... Plasmacytoma | sodium selenite radiation thera... laboratory biom... pharmacological... questionnaire a... | 18 Years - | Stanford University | |
| Docetaxel in Treating Patients With Relapsed Prostate Cancer | NCT00482274 | Prostate Cancer | docetaxel | 18 Years - | OHSU Knight Cancer Institute | |
| Calcitriol in Treating Patients With a Rising PSA Level Following Treatment for Prostate Cancer | NCT00004043 | Prostate Cancer | calcitriol | 18 Years - 120 Years | OHSU Knight Cancer Institute | |
| Orteronel in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer | NCT01866423 | Adenocarcinoma ... Hormone-resista... Recurrent Prost... Stage IV Prosta... | orteronel laboratory biom... | 18 Years - | University of Southern California | |
| Soy Supplements in Treating Patients Undergoing Surgery for Localized Prostate Cancer | NCT00345813 | Prostate Cancer | soy isoflavones soy protein iso... placebo | 18 Years - 120 Years | Wake Forest University Health Sciences | |
| Diindolylmethane in Treating Patients With Stage I or Stage II Prostate Cancer Undergoing Radical Prostatectomy | NCT00888654 | Prostate Cancer | B-Dim Radical Prosate... | 18 Years - 120 Years | Barbara Ann Karmanos Cancer Institute | |
| Vaccine Therapy Plus Interleukin-12 in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy | NCT00015977 | Prostate Cancer | PSA prostate ca... recombinant int... | 18 Years - | University of Chicago | |
| Hormone Therapy and OGX-011 Before Radical Prostatectomy in Treating Patients With Prostate Cancer | NCT00054106 | Prostate Cancer | buserelin custirsen sodiu... flutamide conventional su... neoadjuvant the... | 18 Years - 120 Years | Canadian Cancer Trials Group | |
| Lycopene in Treating Patients Undergoing Radical Prostatectomy for Prostate Cancer | NCT00450749 | Adenocarcinoma ... Stage I Prostat... Stage II Prosta... Stage III Prost... | placebo therapeutic con... laboratory biom... lycopene | 18 Years - | National Cancer Institute (NCI) | |
| Radiation and Androgen Ablation for Prostate Cancer | NCT01517451 | Adenocarcinoma ... | Radiation Thera... Androgen Depriv... | 18 Years - 100 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Intra-operative Optical Imaging With MDX1201-A488 in Patients With Prostate Cancer | NCT02048150 | Adenocarcinoma ... Stage IIB Prost... Stage III Prost... Stage IV Prosta... | anti-PSMA monoc... robot-assisted ... diffuse optical... pharmacological... Laboratory Biom... Questionnaire | 36 Years - 74 Years | City of Hope Medical Center | |
| Tandutinib in Treating Patients With Progressive Prostate Cancer and Bone Metastases | NCT00390468 | Metastatic Canc... Pain Prostate Cancer | Tandutinib | 18 Years - | National Cancer Institute (NCI) | |
| The Prostate Immobilization Device Study | NCT01408706 | Adenocarcinoma ... | Miller Air tip Radiadyne Immob... | 18 Years - | Wheaton Franciscan Healthcare | |
| Sorafenib and Docetaxel in Patients With Prostate Cancer That Did Not Respond to Previous Hormone Therapy | NCT00589420 | Prostate Cancer | docetaxel sorafenib tosyl... | 18 Years - 120 Years | Abramson Cancer Center at Penn Medicine | |
| Collection of Patient-Reported Symptoms and Performance Status Via the Internet | NCT00417040 | Prostate Cancer Breast Cancer Lung Cancer Colorectal Canc... Leukemia Multiple Myelom... | internet-based ... assessment of t... Questionnaire A... | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Metformin Hydrochloride as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Prostate Cancer | NCT01243385 | Prostate Cancer | Metformin | 18 Years - | Swiss Group for Clinical Cancer Research | |
| Radium 223 in Castrate Resistant Prostate Cancer Bone Metastases | NCT02135484 | Prostate Cancer | Alpharadin | 18 Years - | M.D. Anderson Cancer Center | |
| Docetaxel Plus Estramustine in Treating Patients With Metastatic Prostate Cancer | NCT00002775 | Prostate Cancer | docetaxel estramustine ph... | 18 Years - | National Cancer Institute (NCI) | |
| APC8015 and Bevacizumab in Treating Patients With Prostate Cancer | NCT00027599 | Prostate Cancer | bevacizumab prostatic acid ... sipuleucel-T therapeutic aut... in vitro-treate... | - | National Cancer Institute (NCI) | |
| Hsp90 Inhibitor STA-9090 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy | NCT01270880 | Adenocarcinoma ... Hormone-resista... Recurrent Prost... Stage IV Prosta... | Hsp90 inhibitor... laboratory biom... polymerase chai... enzyme-linked i... RNA analysis spectrophotomet... reverse transcr... gene expression... | 18 Years - | Barbara Ann Karmanos Cancer Institute | |
| Radiolabeled Monoclonal Antibody in Treating Patients With Progressive Metastatic Androgen-Independent Adenocarcinoma (Cancer) of the Prostate | NCT00081172 | Prostate Cancer | lutetium Lu 177... | 18 Years - | National Cancer Institute (NCI) |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
